Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities
Open accessAbstract
BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) can develop in individuals who are not overweight. Whether lean persons with NAFLD have lower mortality and lower incidence of cirrhosis, cardiovascular diseases (CVD), diabetes mellitus (DM) and cancer than overweight/obese persons with NAFLD remains inconclusive. We compared mortality and incidence of cirrhosis, CVD, DM and cancer between lean versus non-lean persons with NAFLD. METHODS: This is a retrospective study of adults with NAFLD in a single centre from 2012 to 2021. Primary outcomes were mortality and new diagnosis of cirrhosis, CVD, DM and cancer. Outcomes were modelled using competing risk analysis and Cox proportional hazards regression analysis. RESULTS: A total of 18,594 and 13,420 patients were identified for cross-sectional and longitudinal analysis respectively: approximately 11% lean, 25% overweight, 28% class 1 obesity and 35% class 2-3 obesity. The median age was 51.0 years, 54.6% were women. The median follow-up was 49.3 months. Lean patients had lower prevalence of metabolic diseases at baseline and lower incidence of cirrhosis and DM than non-lean patients and no difference in CVD, any cancer or obesity-related cancer during follow-up. However, lean patients had significantly higher mortality with incidence per 1000 person-years of 16.67, 10.11, 7.37 and 8.99, respectively, in lean, overweight, obesity class 1 and obesity class 2-3 groups respectively. CONCLUSIONS: Lean patients with NAFLD had higher mortality despite lower incidence of cirrhosis and DM, and similar incidence of CVD and cancer and merit similar if not more attention as non-lean patients with NAFLD.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Normal-weight individuals with SLD have a higher mortality risk despite having a lower incidence of cirrhosis and T2D, while the incidence of cardiovascular disease and cancer is similar.
“Normal-weight individuals with SLD have a higher mortality risk despite having a lower incidence of cirrhosis and T2D, while the incidence of cardiovascular disease and cancer is similar. 27”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [27]
The Discussion reports higher mortality and lower incidence of cirrhosis and diabetes among lean patients with NAFLD, with no significant differences in incident cardiovascular disease or cancer. The claim broadens this finding to normal-weight individuals with SLD generally, whereas the study examined NAFLD specifically. (LLM, conf=0.84)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
(2000) · PubMed · Cited by 13,173 · see citing works
(2004) · The Lancet · doi:10.1016/s0140-6736(03)15268-3 · Cited by 12,717 · see citing works
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781 · see citing works
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696 · see citing works
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021 · see citing works
New creatinine- and cystatin C-based equations to estimate GFR without race
Inker, L. A., Eneanya, N. D., Coresh, J., Tighiouart, H., Wang, D., Sang, Y., Crews, D. C., Doria, A., Estrella, M. M., Froissart, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102953 · Cited by 4,695 · see citing works
Adams, L. A., Anstee, Q. M., Tilg, H., & Targher, G. (2017) · Gut · doi:10.1136/gutjnl-2017-313884 · Cited by 1,210 · see citing works
Ye, Q., Zou, B., Yeo, Y. H., Li, J., Huang, D. Q., Wu, Y., Yang, H., Liu, C., Kam, L. Y., Tan, X. X. E., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30077-7 · Cited by 925 · see citing works
Kanwal, F., Shubrook, J. H., Adams, L. A., Pfotenhauer, K., Wai-Sun Wong, V., Wright, E., Abdelmalek, M. F., Harrison, S. A., Loomba, R., Mantzoros, C. S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.049 · Cited by 618 · see citing works
Hsu, C. L., Caussy, C., Imajo, K., Chen, J., Singh, S., Kaulback, K., Le, M., Hooker, J. C., Tu, X. M., Bettencourt, R., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.05.059 · Cited by 422 · see citing works
Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci
Stender, S., Kozlitina, J., Nordestgaard, B. G., Tybjærg‐Hansen, A., Hobbs, H. H., & Cohen, J. C. (2017) · Nature Genetics · doi:10.1038/ng.3855 · Cited by 401 · see citing works
Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients
Leung, J. C., Loong, T. C., Wei, J. L., Wong, G. L., Chan, A. W. H., Choi, P. C., Shu, S. S., Chim, A. M., Chan, H. L., & Wong, V. W. (2016) · Hepatology · doi:10.1002/hep.28697 · Cited by 348 · see citing works
Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stal, P. I., Hultcrantz, R. W., & Kechagias, S. (2017) · Hepatology Communications · doi:10.1002/hep4.1124 · Cited by 311 · see citing works
Masters, R. K., Reither, E. N., Powers, D. A., Yang, Y., Burger, A. E., & Link, B. G. (2013) · American Journal of Public Health · doi:10.2105/ajph.2013.301379 · Cited by 309 · see citing works
Long, M. T., Noureddin, M., & Lim, J. K. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.06.023 · Cited by 299 · see citing works
Hagström, H., Adams, L. A., Allen, A. M., Byrne, C. D., Chang, Y., Grønbæk, H., Ismail, M. H., Jepsen, P., Kanwal, F., Kramer, J. R., et al. (2021) · Hepatology · doi:10.1002/hep.31726 · Cited by 263 · see citing works
Zou, B., Yeo, Y. H., Nguyen, V. H., Cheung, R. C., Ingelsson, E., & Nguyen, M. H. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13069 · Cited by 250 · see citing works
Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver
Feldman, A., Eder, S. K., Felder, T. K., Kedenko, L., Paulweber, B., Stadlmayr, A., Huber-Schönauer, U., Niederseer, D., Stickel, F., Auer, S., et al. (2016) · The American Journal of Gastroenterology · doi:10.1038/ajg.2016.318 · Cited by 239 · see citing works
Fracanzani, A. L., Petta, S., Lombardi, R., Pisano, G., Russello, M., Consonni, D., Marco, V. D., Cammà, C., Mensi, L., Dongiovanni, P., et al. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.04.045 · Cited by 230 · see citing works
Younes, R., Govaere, O., Petta, S., Miele, L., Tiniakos, D., Burt, A., David, E., Vecchio, F. M., Maggioni, M., Cabibi, D., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-322564 · Cited by 205 · see citing works
Non-alcoholic fatty liver disease in lean individuals
Albhaisi, S. A. M., Chowdhury, A., & Sanyal, A. J. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.08.002 · Cited by 179 · see citing works
379 Characteristics and Long-Term Prognosis of Lean Patients With Nonalcoholic Fatty Liver Disease
Cruz, A. C. D., Bugianesi, E., George, J., Day, C. P., Liaquat, H., Charatcharoenwitthaya, P., Mills, P. R., Dam‐Larsen, S., Bjornsson, E. S., Hafliðadóttir, S., et al. (2014) · Gastroenterology · doi:10.1016/s0016-5085(14)63307-2 · Cited by 144 · see citing works
A Fast and Accurate Algorithm to Test for Binary Phenotypes and Its Application to PheWAS
Dey, R., Schmidt, E. M., Abecasis, G. R., & Lee, S. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.05.014 · Cited by 143 · see citing works
Golabi, P., Gerber, L. H., Paik, J. M., Deshpande, R., de Avila, L., & Younossi, Z. M. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100171 · Cited by 141 · see citing works
Chen, V. L., Du, X., Chen, Y., Kuppa, A., Handelman, S. K., Vohnoutka, R. B., Peyser, P. A., Palmer, N. D., Bielak, L. F., Halligan, B. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20870-1 · Cited by 129 · see citing works
Self-citationExtrahepatic Manifestations of Nonalcoholic Fatty Liver Disease
Li, A. A., Ahmed, A., & Kim, D. (2019) · Gut and Liver · doi:10.5009/gnl19069 · Cited by 108 · see citing works
Tang, A. S. P., Ng, C. H., Phang, P. H., Chan, K. E., Chin, Y. H., Fu, C. E., Zeng, R. W., Xiao, J., Tan, D. J. H., Quek, J., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.06.029 · Cited by 106 · see citing works
Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges
Kuchay, M. S., Martínez‐Montoro, J. I., Choudhary, N. S., Fernández‐García, J. C., & Ramos‐Molina, B. (2021) · Biomedicines · doi:10.3390/biomedicines9101346 · Cited by 103 · see citing works
Cozzolino, F., Montedori, A., Abraha, I., Eusebi, P., Grisci, C., Heymann, A. J., Lombardo, G., Mengoni, A., Orso, M., & Ambrosio, G. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218919 · Cited by 95 · see citing works
Ahmed, O. T., Gidener, T., Mara, K. C., Larson, J. J., Therneau, T. M., & Allen, A. M. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.07.016 · Cited by 94 · see citing works
Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease
Kim, Y., Han, E., Lee, J. S., Lee, H. W., Kim, B. K., Kim, M. K., Kim, H. S., Park, J. Y., Kim, D. Y., Ahn, S. H., et al. (2021) · Gut and Liver · doi:10.5009/gnl210084 · Cited by 87 · see citing works
PNPLA3—A Potential Therapeutic Target for Personalized Treatment of Chronic Liver Disease
Dong, X. C. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00304 · Cited by 86 · see citing works
Floyd, J. S., Blondon, M., Moore, K. P., et al. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3921 · Cited by 85 · see citing works
Ha, J., Yim, S. Y., & Karagozian, R. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.11.019 · Cited by 80 · see citing works
Byers, T. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509143331109 · Cited by 78 · see citing works
Ando, T., Ooba, N., Mochizuki, M., Koide, D., Kimura, K., Lee, S. L., Setoguchi, S., & Kubota, K. (2018) · BMC Health Services Research · doi:10.1186/s12913-018-3727-0 · Cited by 78 · see citing works
Alcoholic and Nonalcoholic Fatty Liver Disease and Liver-Related Mortality: A Cohort Study
Chang, Y., Cho, Y. K., Cho, J., Jung, H.-S., Yun, K. E., Ahn, J., Sohn, C. I., Shin, H. C., & Ryu, S. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000074 · Cited by 74 · see citing works
Weinberg, E. M., Trinh, H. N., Firpi, R. J., Bhamidimarri, K. R., Klein, S., Durlam, J., Watkins, S. E., Reddy, K. R., Weiss, M., Zink, R. C., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.06.066 · Cited by 64 · see citing works
Self-citationMoon, J. H., Koo, B. K., & Kim, W. K. (2021) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12719 · Cited by 56 · see citing works
Semmler, G., Wernly, S., Bachmayer, S., Wernly, B., Schwenoha, L., Huber-Schönauer, U., Stickel, F., Niederseer, D., Aigner, E. S., & Datz, C. (2021) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000326 · Cited by 54 · see citing works
Genetic Variant in PNPLA3 Is Associated With Nonalcoholic Fatty Liver Disease in China
Li, Y., Xing, C., Cohen, J. C., & Hobbs, H. H. (2011) · Hepatology · doi:10.1002/hep.24659 · Cited by 42 · see citing works
Hirose, S., Matsumoto, K., Tatemichi, M., Tsuruya, K., Anzai, K., Arase, Y., Shiraishi, K., Suzuki, M., Ieda, S., & Kagawa, T. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241770 · Cited by 40 · see citing works
Holmer, M., Ekstedt, M., Nasr, P., Zenlander, R., Wester, A., Tavaglione, F., Romeo, S., Kechagias, S., Stal, P. I., & Hagström, H. (2022) · Liver International · doi:10.1111/liv.15438 · Cited by 38 · see citing works
Hwang, Y., Kim, N., Yun, C. Y., et al. (2018) · Journal of Cancer Prevention · doi:10.15430/jcp.2018.23.4.183 · Cited by 29 · see citing works
Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease
Arvind, A., Henson, J. B., Osganian, S. A., Nath, C., Steinhagen, L. M., Memel, Z. N., Donovan, A., Balogun, O. O., Chung, R. T., Simon, T. G., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1818 · Cited by 28 · see citing works
Burkholder, D. A., Moran, I. J., DiBattista, J. V., Lok, A. S.-F., Parikh, N. D., & Chen, V. L. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07282-x · Cited by 28 · see citing works
Self-citationCozzolino, F., Bidoli, E., Abraha, I., Fusco, M., Giovannini, G., Casucci, P., Orso, M., Granata, A., Giorgi, M. D., Collarile, P., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020630 · Cited by 22 · see citing works
Kang, M. K., & Park, J.-G. (2021) · Diagnostics · doi:10.3390/diagnostics11050854 · Cited by 19 · see citing works
Jang, D. K., Lee, J., Lee, J. K., & Kim, Y. H. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071013 · Cited by 18 · see citing works
Abraha, I., Serraino, D., Montedori, A., Fusco, M., Giovannini, G., Casucci, P., Cozzolino, F., Orso, M., Granata, A., Giorgi, M. D., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020627 · Cited by 16 · see citing works
Positive predictive value of an algorithm used for cancer surveillance in the U.S. Armed Forces.
Webber, B. J., Rogers, A. E., Pathak, S. R., et al. (2019) · PubMed · Cited by 7 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210 · see citing works
Danpanichkul, P., Suparan, K., Kim, D., & Wijarnpreecha, K. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13010278 · Cited by 54 · see citing works
Self-citation
- Authors
- Wijarnpreecha, K., Li, F., Lundin, S. K., Suresh, D., Song, M. W., Tao, C., Chen, V. L., & Lok, A. S. F.
- Affiliations
- Michigan Medicine (US)
- The University of Texas Health Science Center at Houston (US)
- Corresponding author
- Chen, Vincent L.
- Lok, Anna S. F.
- ORCID
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2023-02-23
- Volume
- 57
- Issue
- 9
- Pages
- 1014-1027
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- PMC
- PMC10682563
- OpenAlex
- W4321597634
- Cited by
- 61
- References
- 51
- Citations by year
- 2026: 14 · 2025: 14 · 2024: 22 · 2023: 11
- FWCI
- 12.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Alimentary Pharmacology & Therapeutics (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nc-nd)
- Deep Blue (University of Michigan) (submittedVersion)
- Funders
- American Association for the Study of Liver Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases (K08 DK132312)
- Topics
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, lean patients, body mass index, mortality, cardiovascular disease, diabetes mellitus, cancer incidence, obesity, metabolic comorbidities
- MeSH terms
- Adult, Cardiovascular Diseases, Cross-Sectional Studies, Diabetes Mellitus, Female, Fibrosis, Humans, Liver Cirrhosis, Male, Middle Aged, Obesity, Retrospective Studies, Overweight, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
